- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT03121092
ACEI/ARB Study in Ambulatory and Day of Surgery Admission Patients (ACE/ARB)
Should Ambulatory Surgery and Day of Surgery Admission Patients Discontinue Angiotensin Converting Enzyme Inhibitors (ACEI's) and Angiotension Receptor Blockers (ARB's) Preoperatively?
Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) are commonly used anti-hypertensive medications that may have implications on the management of a patient undergoing surgery. Limited research has looked at the effects of these medications on perioperative complications and mortality. Some studies conducted on small groups of inpatients with advanced vascular disease undergoing vascular surgery or coronary artery bypass grafting (CABG), suggest exacerbation of hypotension (low blood pressure) in patients who continued taking ACEI's or ARB's on the morning of their procedure. In addition, cases of low blood pressure (BP) that were refractory to standard treatment were reported. One recent retrospective study reported no difference in severe hypotension and only a modest difference in moderate hypotension managed by conventional treatment, but did not adequately address the risk of preoperative hypertension. A study recently published by the investigators (Twersky et al., 2014) in over 600 patients demonstrated no difference in preoperative hypertension in ambulatory surgery and same day admission patients. There has been limited data stratifying the degree of low BP based on severity but these were not done in ambulatory patients, and neither was the degree of high BP from discontinuing these medications addressed. As such, no uniform consensus has been reached and clinicians are unclear as to whether the reported inpatient findings are applicable to the outpatients, since they differ in many respects. The investigators propose to evaluate whether ACEI's and ARB's discontinued preoperatively have a negative impact on perioperative hemodynamics and patient outcome in a group of ambulatory and same day surgical patients. Similar to studies done on inpatients, the investigators will also evaluate patients receiving a standardized general anesthetic for hemodynamics following induction of anesthesia until surgical incision.
The investigators hypothesize that continuing ACEI's and ARB's in the preoperative period does not result in an increased risk of severe hypotension (low blood pressure) following induction of general anesthesia.
Study Overview
Study Type
Enrollment (Actual)
Phase
- Not Applicable
Contacts and Locations
Study Locations
-
-
New York
-
Brooklyn, New York, United States, 11203
- SUNY Downstate Medical Center
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
- patients over the age of 18
- patients scheduled to undergo any surgical procedure on an ambulatory basis or on a same day admission basis
- patients undergoing general anesthesia by Laryngeal Mask Airway (LMA)
- patients taking chronic ACEI or ARB drug treatment for hypertension for more than 6 weeks
- patients on diuretics and/or beta blockers and/or calcium channel blockers for hypertension in addition to the ACEI or ARB (alone or in combination) for hypertension may be included
- patients taking any cardiovascular medications may be included
Exclusion Criteria:
- patients taking both an ACEI and an ARB simultaneously
- patients taking ACEI or ARB for less than 6 weeks
- patients with uncontrolled hypertension during pre-surgical testing (PST) visit, defined as Systolic (SBP) > 180 or Diastolic (DBP) > 100 (Seventh Report of the Joint National Committee on Prevention, Detection, Evaluation, and Treatment of High Blood Pressure JNC 7)
- patients with history of unstable heart disease, refractory congestive heart failure, hypertensive stroke, mini stroke, stroke or heart attack within the past 6 months
- emergency surgery
- patients who are pregnant
- patients whose surgery requires endotracheal intubation
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Health Services Research
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: Single
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
|---|---|
|
No Intervention: Discontinue ACEI or ARB
Patients in this group will not take the ACE or ARB 24 hours prior to their procedure.
|
|
|
Active Comparator: Continue ACEI or ARB
Patients in this group will take an ACE or ARB on the day of surgery.
|
Angiotensin converting enzyme inhibitors (ACEI's) and Angiotensin receptor blockers (ARB's) - commonly used anti-hypertensive medications
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Measure Description |
Time Frame |
|---|---|---|
|
Presence of moderate hypotension
Time Frame: Through study completion, projected 2-3 years
|
Presence of moderate hypotension (SBP<90 or a change of >30% from pre-induction baseline), in the intraoperative setting and in the post-anesthesia care unit
|
Through study completion, projected 2-3 years
|
|
Presence of severe hypotension
Time Frame: Through study completion, projected 2-3 years
|
Presence of severe hypotension (SBP<65) between induction and incision
|
Through study completion, projected 2-3 years
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
|---|---|
|
The prevalence of cancellation of surgery secondary to unstable BP
Time Frame: Through study completion, projected 2-3 years
|
Through study completion, projected 2-3 years
|
|
The number and dose of medications to treat BP
Time Frame: Through study completion, projected 2-3 years
|
Through study completion, projected 2-3 years
|
|
prevalence of adverse effects (increased length of stay in the PACU, unanticipated hospitalizations, myocardial ischemia, stroke, death)
Time Frame: Through study completion, projected 2-3 years
|
Through study completion, projected 2-3 years
|
Collaborators and Investigators
Investigators
- Principal Investigator: Ketan Shevde, MD, State University of New York - Downstate Medical Center
- Principal Investigator: Rebecca Twersky, MD, MPH, Memorial Sloan Kettering Cancer Center
Publications and helpful links
Study record dates
Study Major Dates
Study Start (Actual)
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Actual)
Study Record Updates
Last Update Posted (Actual)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Additional Relevant MeSH Terms
Other Study ID Numbers
- 303066-1
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Hypertension
-
National Taiwan University Hospital Hsin-Chu BranchRecruitingHypertension,Essential | Hypertension, MaskedTaiwan
-
BackBeat Medical IncNot yet recruitingHypertension, Systolic | Hypertension (HTN) | Heart Failure With Preserved Ejection Fraction (HFpEFGeorgia
-
Xuanwu Hospital, BeijingNot yet recruiting
-
Shenzhen Salubris Pharmaceuticals Co., Ltd.Not yet recruiting
-
Instituto de Cardiologia do Rio Grande do SulCompletedHypertension (HTN) | Hypertension ArterialBrazil
-
University of Alabama at BirminghamTroy UniversityCompletedHypertension | Hypertension, Resistant to Conventional Therapy | Uncontrolled Hypertension | Hypertension, White CoatUnited States
-
Franz Rischard, DOAcceleron Pharma, Inc., a wholly-owned subsidiary of Merck & Co., Inc., Rahway...Not yet recruitingPulmonary Hypertension | Pulmonary Arterial Hypertension (PAH)United States
-
Abant Izzet Baysal UniversityNot yet recruitingPRIMARY HYPERTENSIONTurkey (Türkiye)
-
SingHealth PolyclinicsNanyang PolytechnicEnrolling by invitationHypertension,EssentialSingapore
-
Hacettepe UniversityBozok UniversityCompletedHypertension | Arterial Hypertension | Systemic HypertensionTurkey (Türkiye)
Clinical Trials on ACEI or ARB
-
Ain Shams UniversityNot yet recruitingNephrotic Syndrome
-
Novartis PharmaceuticalsNot yet recruiting
-
Chinese University of Hong KongTerminatedHypertension | Non-DippingHong Kong
-
University Hospital, Basel, SwitzerlandCompletedRAS Peptide Profile in Healthy VolunteersSwitzerland
-
Capital Institute of Pediatrics, ChinaRecruitingHenoch Schönlein Purpura NephritisChina
-
Lawson Health Research InstituteCompleted
-
First Affiliated Hospital, Sun Yat-Sen UniversityRecruitingPrimary Membranous NephropathyChina
-
University of PennsylvaniaUniversity of Arizona; Jordana B. Cohen, MD, MSCE; Thomas C. Hanff, MD, MPH; Department... and other collaboratorsCompleted
-
University Hospital, Gentofte, CopenhagenCompleted
-
Children's Hospital of Fudan UniversityFirst Affiliated Hospital, Sun Yat-Sen University; Shandong Provincial Hospital and other collaboratorsCompletedKidney Diseases | Proteinuria | Hereditary NephropathyChina